(Total Views: 430)
Posted On: 08/24/2025 8:32:42 AM
Post# of 156696
Then from your posting link on this patient.....
0131] This subject, Patient A, is a 78-year-old female with a diagnosis of metastatic breast cancer, stage IV. The subject previously received Taxotere/Herceptin/Pertuzumab as frontline therapy for metastatic HER2 positive breast cancer. She had partial response for her systemic disease, but then developed diffuse brain metastases (systemic disease stable).
__
Other than brain aspect, are you also thinking she is one two patients Dr. J just said are stable & minimum treatment @ 5 years out ?
We have 3 @ 5 yrs.
2 stable.
1 NED.
0131] This subject, Patient A, is a 78-year-old female with a diagnosis of metastatic breast cancer, stage IV. The subject previously received Taxotere/Herceptin/Pertuzumab as frontline therapy for metastatic HER2 positive breast cancer. She had partial response for her systemic disease, but then developed diffuse brain metastases (systemic disease stable).
__
Other than brain aspect, are you also thinking she is one two patients Dr. J just said are stable & minimum treatment @ 5 years out ?
We have 3 @ 5 yrs.
2 stable.
1 NED.
(4)
(0)
